Cure8 research brief
The study presents a preclinical strategy to concentrate an existing antihistamine drug in the colon and reduce systemic exposure, which could improve local efficacy and safety for IBD treatment if later validated in humans.
Researchers and clinicians involved in IBD drug development, translational researchers interested in colon-targeted prodrugs, and pharma scientists exploring drug-repositioning strategies.
The researchers synthesized three epinastine (EPNT) prodrugs linked to 5-ASA or amino-acid–conjugated 5-ASA via azo bonds (EAS, EAS-Asp, EAS-Glu).
In lab and animal tests the prodrugs were stable in the upper gut, cleaved in cecal contents, delivered more EPNT to the colon than oral EPNT, and produced greater anti-colitis effects than EPNT or sulfasalazine in a rat chemical colitis model.
Mechanism and evidence level The authors report that oral EPNT prodrugs increased colonic AMPK, Nrf2, and HO-1 protein levels and that inhibiting HO-1 reduced efficacy, suggesting the AMPK–Nrf2–HO-1 pathway contributes to the effect. These results are from preclinical in vitro and rat-model experiments, not human studies.
Implications This is early-stage, mechanistic drug-discovery research suggesting colon-targeted epinastine prodrugs could be a candidate for further development as anti-IBD agents; it does not establish safety or effectiveness in people.
This article reports preclinical laboratory and rat-model findings (abstract-level summary). It is not clinical evidence — human safety and efficacy remain untested. The structured content is based on the paper abstract provided by the journal.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Research Foundation of Korea, award 2021R1I1A3A0403710411
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring ways to deliver drugs selectively to inflamed gut tissue in IBD to boost local effectiveness and reduce systemic side effects. Progress in smart nanoparticles and hydrogels could eventually...
The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...
Finding reliable diagnostic biomarkers could help detect UC earlier and clarify immune mechanisms that drive disease; GPR97 is proposed here as such a marker and a possible immunomodulatory target, which may interest...
